Mesoblast Price Target Raised to $11.00/Share From $4.00 by Piper Sandler
Mesoblast Analyst Ratings
Piper Sandler Upgrades Mesoblast(MESO.US) to Buy Rating
Mesoblast Limited (MEOBF) Was Downgraded to a Hold Rating at Jefferies
Mesoblast Analyst Ratings
Mesoblast Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Aprea Therapeutics (APRE), Biogen (BIIB) and Mesoblast Limited (OtherMEOBF)
Mesoblast (MESO) Gets a Hold From Piper Sandler
Mesoblast Limited (MEOBF) Receives a Buy From Jefferies
Mesoblast (MESO) Gets a Hold From Piper Sandler
Jefferies Keeps Their Buy Rating on Mesoblast Limited (MEOBF)
Analysts Are Bullish on These Healthcare Stocks: Guangzhou Baiyunshan Pharmaceutical Holdings Company (GZPHF), Mesoblast Limited (MEOBF)
Analysts Offer Insights on Healthcare Companies: Haemonetics (HAE), Mesoblast (MESO) and HealthStream (HSTM)
Cantor Fitzgerald Reiterates Overweight on Mesoblast, Maintains $17 Price Target
Mesoblast Analyst Ratings
Analyst Bullish On Cell Therapy Player Mesoblast, But Cuts Price Target
William Blair Reaffirms Their Hold Rating on Mesoblast (MESO)
Cantor Fitzgerald Maintains Overweight on Mesoblast, Lowers Price Target to $17
Mesoblast Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Cooper Co (COO) and Mesoblast (MESO)